AH Bio Fund I, L.P. - 20 Jul 2026 SCHEDULE 13G Report for Freenome, Inc. Common Stock, par value $0.0001 per share

Filing manager: AH Bio Fund I, L.P.
Reporting owner: Marc L. Andreessen
Security: Freenome, Inc. Common Stock, par value $0.0001 per share
Beneficially owned shares: 5,571,599 shares
Large-stake signal: Form
SCHEDULE 13G
Passive or exempt beneficial ownership filing.
Ownership
5.2%
Beneficial ownership of this reported class.
Shares
5,571,599 shares
Shares beneficially owned as disclosed.
Event date
20 Jul 2026
Date tied to the ownership event or amendment.
Accepted by SEC
27 Jul 2026
EDGAR acceptance date.
How to read this large-stake filing
Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
Compare this filing with the holder history and issuer page before treating the percentage as a current position.
Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Class ownership: 5.2%
Shares outstanding: 107,146,135 shares
SEC form: SCHEDULE 13G
Accepted by SEC: 27 Jul 2026, 17:10:28 UTC
Event date: 20 Jul 2026
Source filing: View source filing

Key filing fact

AH Bio Fund I, L.P. disclosed 5.2% ownership in Freenome, Inc. Common Stock, par value $0.0001 per share on 20 Jul 2026.

Key facts

AH Bio Fund I, L.P. filed SCHEDULE 13G for Freenome, Inc. Common Stock, par value $0.0001 per share.
Disclosed ownership: 5.2%.
Date of event: 20 Jul 2026.

This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

Reporting persons

Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name	Ownership	Shares owned	Sole voting power	Shared voting power	Signature	Title
AH Bio Fund I, L.P.	3.1%	3,327,525	3,327,525	0	/s/ Phil Hathaway	By AH Equity Partners Bio I, L.L.C., Its General Partner, By Phil Hathaway, Chief Operating Officer (See Note 1)
AH Equity Partners Bio I, L.L.C.	3.1%	3,327,525	3,327,525	0	/s/ Phil Hathaway	By Phil Hathaway, Chief Operating Officer
Andreessen Horowitz LSV Fund II, L.P.	1%	1,038,814	1,038,814	0	/s/ Phil Hathaway	By AH Equity Partners LSV II, L.L.C., Its General Partner, By Phil Hathaway, Chief Operating Officer (See Note 2)
AH Equity Partners LSV II, L.L.C.	1%	1,038,814	1,038,814	0	/s/ Phil Hathaway	By Phil Hathaway, Chief Operating Officer
CLF Partners, LP	0%	6,207	6,207	0	/s/ Phil Hathaway	By AH Equity Partners V, L.L.C., Its General Partner, By Phil Hathaway, Chief Operating Officer
AH Equity Partners V, L.L.C.	0%	6,207	6,207	0	/s/ Phil Hathaway	By Phil Hathaway, Chief Operating Officer
AH Parallel Fund IV, L.P.	1.1%	1,199,053	1,199,053	0	/s/ Phil Hathaway	By AH Equity Partners IV (Parallel), L.L.C., Its General Partner, By Phil Hathaway, Chief Operating Officer (See Note 3)
AH Equity Partners IV (Parallel), L.L.C.	1.1%	1,199,053	1,199,053	0	/s/ Phil Hathaway	By Phil Hathaway, Chief Operating Officer
Marc L. Andreessen	5.2%	5,571,599	0	5,571,599	/s/ Phil Hathaway	By Phil Hathaway, Attorney-in-Fact
Benjamin A. Horowitz	5.2%	5,571,599	0	5,571,599	/s/ Phil Hathaway	By Phil Hathaway, Attorney-in-Fact

CIK / CUSIP context first

Broader feeds